Mayank Mamtani
Stock Analyst at B. Riley Securities
(4.45)
# 296
Out of 4,876 analysts
125
Total ratings
44.55%
Success rate
34.57%
Average return
Main Sectors:
Stocks Rated by Mayank Mamtani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNOV MediciNova | Maintains: Buy | $6 → $5 | $1.30 | +284.62% | 2 | Jun 16, 2025 | |
| MGNX MacroGenics | Maintains: Neutral | $5 → $3 | $1.19 | +152.10% | 2 | May 20, 2025 | |
| MDGL Madrigal Pharmaceuticals | Reiterates: Buy | $422 → $460 | $300.75 | +52.95% | 12 | May 2, 2025 | |
| HROW Harrow | Maintains: Buy | $69 → $65 | $30.88 | +110.49% | 2 | Apr 1, 2025 | |
| VXRT Vaxart | Maintains: Buy | $2.5 → $2 | $0.49 | +304.45% | 6 | Mar 27, 2025 | |
| TRVI Trevi Therapeutics | Reiterates: Buy | $11 → $20 | $5.62 | +255.87% | 3 | Mar 19, 2025 | |
| LCTX Lineage Cell Therapeutics | Maintains: Buy | $4 → $3 | $0.94 | +220.79% | 2 | Mar 14, 2025 | |
| DNLI Denali Therapeutics | Reiterates: Buy | $38 → $35 | $14.10 | +148.23% | 2 | Mar 5, 2025 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Buy | $51 → $38 | $16.08 | +136.32% | 7 | Feb 14, 2025 | |
| VKTX Viking Therapeutics | Reiterates: Buy | $109 → $96 | $26.52 | +261.99% | 2 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $25.76 | +132.92% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1 → $1.5 | $0.30 | +400.00% | 3 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 → $26 | $6.37 | +308.16% | 19 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33 | $13.20 | +150.00% | 1 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $20 | $3.50 | +471.43% | 9 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $34 | $36.72 | -7.41% | 13 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $122 → $92 | $33.16 | +177.44% | 3 | Jun 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $140 | $6.05 | +2,214.05% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $90 | $1.83 | +4,818.03% | 5 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $160 | $4.76 | +3,261.34% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $5 | $1.97 | +153.81% | 3 | Aug 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $44 | $1.75 | +2,414.29% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $90 | $1.82 | +4,845.05% | 4 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 → $7 | $5.33 | +31.33% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9,750 → $4,500 | $1.02 | +441,076.47% | 3 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $500 → $270 | $1.01 | +26,632.67% | 2 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $138 → $77 | $13.33 | +477.64% | 2 | Jan 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,980 → $1,440 | $1.81 | +79,458.01% | 3 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $2.33 | +71.67% | 2 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $47 → $39 | $105.27 | -62.95% | 2 | Mar 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $34 | $3.75 | +806.67% | 1 | Mar 13, 2020 |
MediciNova
Jun 16, 2025
Maintains: Buy
Price Target: $6 → $5
Current: $1.30
Upside: +284.62%
MacroGenics
May 20, 2025
Maintains: Neutral
Price Target: $5 → $3
Current: $1.19
Upside: +152.10%
Madrigal Pharmaceuticals
May 2, 2025
Reiterates: Buy
Price Target: $422 → $460
Current: $300.75
Upside: +52.95%
Harrow
Apr 1, 2025
Maintains: Buy
Price Target: $69 → $65
Current: $30.88
Upside: +110.49%
Vaxart
Mar 27, 2025
Maintains: Buy
Price Target: $2.5 → $2
Current: $0.49
Upside: +304.45%
Trevi Therapeutics
Mar 19, 2025
Reiterates: Buy
Price Target: $11 → $20
Current: $5.62
Upside: +255.87%
Lineage Cell Therapeutics
Mar 14, 2025
Maintains: Buy
Price Target: $4 → $3
Current: $0.94
Upside: +220.79%
Denali Therapeutics
Mar 5, 2025
Reiterates: Buy
Price Target: $38 → $35
Current: $14.10
Upside: +148.23%
Arrowhead Pharmaceuticals
Feb 14, 2025
Reiterates: Buy
Price Target: $51 → $38
Current: $16.08
Upside: +136.32%
Viking Therapeutics
Feb 7, 2025
Reiterates: Buy
Price Target: $109 → $96
Current: $26.52
Upside: +261.99%
Jan 8, 2025
Initiates: Buy
Price Target: $60
Current: $25.76
Upside: +132.92%
Dec 19, 2024
Upgrades: Buy
Price Target: $1 → $1.5
Current: $0.30
Upside: +400.00%
Oct 10, 2024
Reiterates: Buy
Price Target: $23 → $26
Current: $6.37
Upside: +308.16%
Sep 19, 2024
Initiates: Buy
Price Target: $33
Current: $13.20
Upside: +150.00%
Aug 12, 2024
Reiterates: Buy
Price Target: $20
Current: $3.50
Upside: +471.43%
Aug 7, 2024
Maintains: Buy
Price Target: $29 → $34
Current: $36.72
Upside: -7.41%
Jun 4, 2024
Maintains: Buy
Price Target: $122 → $92
Current: $33.16
Upside: +177.44%
Oct 13, 2023
Initiates: Buy
Price Target: $140
Current: $6.05
Upside: +2,214.05%
Apr 10, 2023
Maintains: Buy
Price Target: $210 → $90
Current: $1.83
Upside: +4,818.03%
Mar 29, 2023
Reiterates: Buy
Price Target: $160
Current: $4.76
Upside: +3,261.34%
Aug 19, 2022
Downgrades: Neutral
Price Target: $11 → $5
Current: $1.97
Upside: +153.81%
Aug 11, 2022
Maintains: Buy
Price Target: $58 → $44
Current: $1.75
Upside: +2,414.29%
Jul 14, 2022
Maintains: Buy
Price Target: $120 → $90
Current: $1.82
Upside: +4,845.05%
May 24, 2022
Downgrades: Neutral
Price Target: $14 → $7
Current: $5.33
Upside: +31.33%
Jan 24, 2022
Maintains: Buy
Price Target: $9,750 → $4,500
Current: $1.02
Upside: +441,076.47%
Nov 30, 2021
Maintains: Buy
Price Target: $500 → $270
Current: $1.01
Upside: +26,632.67%
Jan 15, 2021
Downgrades: Neutral
Price Target: $138 → $77
Current: $13.33
Upside: +477.64%
May 22, 2020
Downgrades: Neutral
Price Target: $1,980 → $1,440
Current: $1.81
Upside: +79,458.01%
Apr 3, 2020
Maintains: Buy
Price Target: $8 → $4
Current: $2.33
Upside: +71.67%
Mar 18, 2020
Maintains: Buy
Price Target: $47 → $39
Current: $105.27
Upside: -62.95%
Mar 13, 2020
Maintains: Buy
Price Target: $43 → $34
Current: $3.75
Upside: +806.67%